Skip to content
DataLookout
Menu

NCT07885956

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults

StatusNot Yet Recruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage of participants reporting local reactions
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting systemic events
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting adverse events
Timeframe: Through 1 month after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions
Timeframe: Through 18 months after vaccination
Percentage of participants reporting serious adverse events
Timeframe: Through 18 months after vaccination

Arms and interventions

Group 1Experimental

Participants will receive a single open-label, intramuscular injection of RSVpreF (Regimen A) as a revaccination.

Group 2Experimental

Participants will receive a single open-label, intramuscular injection of RSVpreF (Regimen B) as a revaccination.

Group 3No intervention

Participants will not be revaccinated.

Biologicals: RSVpreF (Regimen A), RSVpreF (Regimen B)